Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/41845
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Martin C.A. | en |
dc.contributor.author | Mcgrath B.P. | en |
dc.date.accessioned | 2021-05-14T14:21:05Z | en |
dc.date.available | 2021-05-14T14:21:05Z | en |
dc.date.copyright | 2014 | en |
dc.date.created | 20140115 | en |
dc.date.issued | 2014-01-15 | en |
dc.identifier.citation | Clinical and Experimental Pharmacology and Physiology. 41 (1) (pp 22-29), 2014. Date of Publication: January 2014. | en |
dc.identifier.issn | 0305-1870 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/41845 | en |
dc.description.abstract | Summary: Numerous studies have examined whether white-coat hypertension (WCHT) is associated with increased cardiovascular risk, but with definitions of WCHT that were not sufficiently robust, results have been inconsistent. The aim of the present review was to standardize the evidence by only including studies that used a definition of WCHT consistent with international guidelines. Published studies were reviewed for data on vascular dysfunction, target organ damage, risk of future sustained hypertension and cardiovascular events. White-coat hypertension has a population prevalence of approximately 15% and is associated with non-smoking and slightly elevated clinic blood pressure. Compared with normotensives, subjects with WCHT are at increased cardiovascular risk due to a higher prevalence of glucose dysregulation, increased left ventricular mass index and increased risk of future diabetes and hypertension. In conclusion, management of a patient with WCHT should focus on cardiovascular risk factors, particularly glucose intolerance, not blood pressure alone. © 2013 Wiley Publishing Asia Pty Ltd. | en |
dc.language | English | en |
dc.language | en | en |
dc.publisher | Blackwell Publishing (550 Swanston Street, Carlton South VIC 3053, Australia) | en |
dc.title | White-coat hypertension. | en |
dc.type | Article | en |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/1440-1681.12114 | en |
dc.publisher.place | Australia | en |
dc.identifier.pubmedid | 23682974 [http://www.ncbi.nlm.nih.gov/pubmed/?term=23682974] | en |
dc.identifier.source | 372024220 | en |
dc.identifier.institution | (Martin, Mcgrath) Monash University, Melbourne, VIC., Australia (Martin, Mcgrath) Monash Health, Melbourne, VIC., Australia (Martin) Australian Catholic University, Melbourne, VIC., Australia | en |
dc.description.address | B.P. Mcgrath, Monash Doctors Education, Monash Health, Clayton, VIC. 3168, Australia. E-mail: barry.mcgrath@monash | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2014 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | Cardiovascular risk Glucose intolerance Isolated clinic hypertension White-coat hypertension | en |
dc.identifier.authoremail | Mcgrath B.P.; barry.mcgrath@monash | en |
item.fulltext | No Fulltext | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Article | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.